Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
| SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM | ||||
| Symptom / effect | Talk with your doctor or pharmacist | Stop taking drug and call your doctor or pharmacist | ||
| Only if severe | In all cases | |||
| Rare | Allergic reactions: swelling of the mouth and throat, shortness of breath, hives, severe itching and rash |
√ | ||
This is not a complete list of side effects. For any unexpected effects while taking PATADAY, contact your doctor or pharmacist.
HOW TO STORE IT
Store at room temperature or between 4-25°C.
Throw away the bottle at the end of your treatment.
Keep out of the reach and sight of children.
REPORTING SIDE EFFECTS
You can report any suspected side effects associated with the use of health products to Health Canada by:
PATADAY™
(olopatadine hydrochlorideophthalmic) Solution
PATADAY™ (olopatadine hydrochloride ophthalmic solution) 0.2% is a sterile ophthalmic solution containing olopatadine for topical administration to the eyes. Olopatadine hydrochloride is a white, crystalline, water-soluble powder with a molecular weight of 373.88 and a molecular formula of C21H23NO3 • HCl.
The chemical structure is presented below:
 |
Chemical Name: 11-[(Z)-3(Dimethylamino) propylidene]-6-11dihydrodibenz[b,e] oxepin-2-acetic acid, hydrochloride
Each mL of PATADAY™ (olopatadine hydrochloride ophthalmic solution) solution contains: Active: 2.22 mg olopatadine hydrochloride equivalent to 2 mg olopatadine. Inactives: povidone; dibasic sodium phosphate; sodium chloride; edentate disodium; benzalkonium chloride 0.01% (preservative); hydrochloric acid/sodium hydroxide (adjust pH); and purified water.
It has a pH of approximately 7and an osmolality of approximately 300 mOsm/kg.
PATADAY® (olopatadine hydrochloride ophthalmic solution) is indicated for the treatment of ocular itching associated with seasonal allergic conjunctivitis.
No overall differences in safety and effectiveness have been observed between elderly and other adult patients.
The effectiveness of PATADAY has not been established in paediatric patients <18 years of age. No overall difference in safety has been observed between paediatric and adult patients.
No special dosage considerations are necessary for PATADAY.
The recommended dose is one drop in each affected eye once a day.
No dosage adjustment is required in hepatic or renal impairment.
If a dose is missed, a single drop should be taken as soon as possible before reverting to regular routine. Do not use a double dose to make up for the one missed.
Store at 4° - 25°C. Discard the container at the end of treatment. Keep out of the reach and sight of children.
Each mL of PATADAY contains:
Medicinal ingredient: 2.22 mg olopatadine hydrochloride equivalent to 2 mg olopatadine.
Preservative: benzalkonium chloride 0.01%.
Non-medicinal ingredients: dibasic sodium phosphate, edetate disodium, povidone, sodium chloride, hydrochloric acid/sodium hydroxide (to adjust pH), and purified water.
PATADAY has a pH of approximately 7 and an osmolality of approximately 300 mOsm/kg.
PATADAY is supplied in a white, round, low density polyethylene DROP-TAINER® dispenser bottle with a natural low density polyethylene dispensing plug and a white polypropylene cap. Tamper evidence is provided with a shrink band around the closure and neck area of the package.
Net contents are 2.5 mL in a 4 mL bottle.
REFERENCES
1. Abelson MB, Schaefer K. Conjunctivitis of allergic origin: Immunologic mechanisms and current approaches to therapy. Surv Ophthalmol 38:115-132, 1993.
2. Allansmith MR, Ross R. Ocular allergy. Clinical Allergy 18:1-13, 1988.
3. Allansmith MR, Ross R. Ocular allergy and mast cell stabilizers. Survey of Ophthalmology 30:226-244, 1986.
5. Friedlander MH. Conjunctival provocative tests: a model of human ocular allergy. Trans Am Ophthalmologic Soc. 577-597, 1989.
7. Miller S, Cook E, Graziano F, Spellman J, Yanni J. Human conjunctival mast cell responses in vitro to various secretagogues. Ocular Immunol Inflamm 4:39-49, 1996.
15. Yanni JM, Weimer LK, Sharif NA, Xu SX, Gamache DA, Spellman JM. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Arch Ophthalmol 117:643-647, 1999.
Prepared by: Novartis Pharmaceuticals Canada Inc. Revised: Apr 2018
In clinical trials involving 1137 patients dosed with long-term ophthalmic topical therapy, PATADAY was administered once-daily for 4 to 12 weeks. The most frequently reported treatment-related undesirable effects were headache (0.8%), eye irritation (0.5%), dry eye (0.4%), and eyelid margin crusting (0.4%). No serious adverse drug reactions related to PATADAY were reported in the clinical trials.
Because clinical trials are conducted under very specific conditions, the adverse drug reaction rates observed in the clinical trials may not reflect the rates observed in practice and should also not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.
No treatment-related adverse drug reactions occurred at an incidence ≥ 1%.
The most frequently reported adverse drug reactions (>0.1%) are presented in Table 1.
Table 1: Treatment-Related Adverse Drug Reactions >0.1% – Long-Term Exposure
| MedDRA Preferred Term (Version 11.0) | PATADAY N = 1137 (%) | Placebo N = 631 (%) |
| Eye Disorders | ||
| Eye Irritation | 0.5% | 0.6% |
| Dry Eye | 0.4% | 0.5% |
| Eyelid Margin Crusting | 0.4% | |
| Eye Pruritus | 0.2% | 0.3% |
| Gastrointestinal Disorders | ||
| Dry Mouth | 0.2% | |
| Nervous System Disorders | 0.8% | |
| Dysgeusia | 0.4% | |
Additional treatment-related adverse drug reactions that occurred at an incidence of 0.1% included the following:
Eye disorders: asthenopia, eye swelling, eyelid disorder, eyelids pruritus, ocular hyperaemia, and vision blurred;
Investigations: heart rate increased;
Respiratory, Thoracic, and Mediastinal disorders: nasal dryness
Approximately 5.4 million units of PATADAY have been sold worldwide. The reporting rate of all reaction terms reported between 22 December 2004 and 31 August 2009 was 0.005%, and no single reaction term occurred with a reporting rate greater than 0.0007%. No post-market reports of serious adverse reactions have been received to date. The most frequent events reported being eye irritation, ocular hyperaemia, eye pain and vision blurred. There were no new major findings bearing on the established overall safety profile of PATADAY. Other events include dizziness, eye discharge, punctate keratitis, keratitis, erythema of eyelid, dermatitis contact, fatigue, hypersensitivity, ocular discomfort, lacrimation increased and nausea.
No clinical interaction studies have been conducted with PATADAY. In vitro studies have shown that olopatadine does not inhibit metabolic reactions which involve cytochrome P-450 isoenzymes 1A2, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4. Olopatadine is moderately bound to plasma proteins (approximately 55%). These results indicate that olopatadine is unlikely to result in interactions with other concomitantly administered medications. Due to the low systemic exposure following topical ocular dosing, it is unlikely that PATADAY would interfere with immediate hypersensitivity skin testing.
Interactions with other drugs, food, herbal products or laboratory tests have not been established.
Included as part of the "PRECAUTIONS" Section
For topical ocular use only. Not for injection or oral use.
As with any eye drop, to prevent contamination of the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use.
Patients should be advised not to wear contact lenses if their eye(s) are red.
PATADAY should not be used to treat contact lens related irritation. The preservative in PATADAY, benzalkonium chloride, may cause eye irritation and is known to discolour soft contact lenses. Contact with soft contact lenses should be avoided. Patients must be instructed to remove contact lenses prior to application of PATADAY, and wait at least 15 minutes before they insert their contact lenses.
If using other eye drops, patients should wait at least five minutes between putting in PATADAY and the other drops. Eye ointments should be applied last.
Olopatadine is a non-sedating anti-histamine. Temporary blurred vision or other visual disturbances, after the use of PATADAY, may affect the ability to drive or use machines. If blurred vision occurs after instillation, patients must wait until vision clears before driving or using machinery.
Studies have not been performed to evaluate the effect of topical ocular administration of olopatadine on human fertility.
There are no adequate and well controlled studies in pregnant women. Studies in animals with olopatadine have shown reproductive toxicity following systemic administration considered sufficiently in excess of the maximum human exposure. Olopatadine was found not to be teratogenic in rats and rabbits at oral doses >90,000 and >60,000 times the maximum recommended ocular human use level, respectively (see Nonclinial Toxicology). Because animal studies are not always predictive of human responses, PATADAY should be used in pregnant women only if the potential benefit to the mother justifies the potential risk to the embryo or fetus.
Olopatadine has been identified in the milk of nursing rats following oral administration. It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in human breast milk. Nevertheless, caution should be exercised when PATADAY is administered to a nursing mother.
Effectiveness in paediatric patients has not been established. No overall difference in safety has been observed between paediatric and adult patients.
No overall differences in safety and effectiveness have been observed between elderly and other adult patients.
The acute toxicity of olopatadine hydrochloride has been investigated in mice, rats and dogs. Mice and rats demonstrated that olopatadine hydrochloride was not an acute toxicity hazard with oral LD50 values greater than 1150 mg/kg and 3870 mg/kg for mice and rats, respectively.
Subchronic and chronic oral toxicity studies in rats and dogs demonstrated that the liver and kidney were target organs for olopatadine hydrochloride toxicity. In rats, ophthalmology and hematology parameters were unaffected following chronic administration of olopatadine hydrochloride. In chronic dog studies, ophthalmology, hematology, blood chemistry and organ weight parameters were unaffected by olopatadine hydrochloride administration.
A one-month topical ocular study was conducted with 0.1% QID or 0.2% olopatadine hydrochloride QID and HID ophthalmic solution in New Zealand White (NZW) rabbits. No signs of pharmacotoxicity were observed. Slit-lamp and indirect ocular evaluations and pachymetry revealed no treatment-related findings. Clinical pathology data and histopathology were unremarkable.
Two one-day topical ocular studies were conducted in NZW rabbits with 0.2% olopatadine hydrochloride formulations containing povidone. Each animal received two drops of the test article to one eye every 30 minutes for a total of ten doses. Slit lamp biomicroscopic examinations were conducted at 1, 2, 3 days following treatment. No significant ocular irritation was observed.
Chronic topical ocular studies were conducted with olopatadine hydrochloride in rabbits and monkeys. Administration of olopatadine hydrochloride at concentrations of 0.1, 0.5 and 1.0% QID to NZW rabbits elicited no signs of pharmacotoxicity. No treatment-related findings were observed during slit-lamp and indirect ocular evaluations and pachymetry measurements. Clinical pathology data and histopathology were unremarkable. Similar findings were observed following six months of topical ocular administration of olopatadine hydrochloride at concentrations of 0.1, 0.2 and 0.5% QID to cynomolgus monkeys and following three months of topical ocular administration of formulations containing 0.2 and 0.4% of olopatadine hydrochloride with povidone TID to rabbits.
Olopatadine was found not to be teratogenic in rats and rabbits. However, rats treated at 600 mg/kg/day, or 150,000 times the MROHD and rabbits treated at 400 mg/kg/day, or approximately 100,000 times the MROHD, during organogenesis showed a decrease in live fetuses. In addition, rats treated with 600 mg/kg/day of olopatadine during organogenesis showed a decrease in fetal weight. Further, rats treated with 600 mg/kg/day of olopatadine during late gestation through the lactation period showed a decrease in neonatal survival and body weight.
Olopatadine hydrochloride was demonstrated to have a low potential for antigenicity when tested in mice and guinea pigs or in an in vitro passive hemagglutination test.
Olopatadine was tested in a series of in vitro and in vivo mutagenesis studies. The results of these studies demonstrated that treatment with olopatadine did not induce genetic mutations or chromosomal aberrations. Long-term carcinogenicity studies in rats and mice also demonstrated that treatment with olopatadine did not increase the potential for cancer up to 500 mg/kg/day or over 200,000 fold greater than the maximum recommended daily dose.
For management of suspected drug overdose, consult your regional poison control centre.
No data are available in humans regarding overdose by accidental or deliberate ingestion of PATADAY. No reports of overdose were received during the clinical studies of PATADAY.
If a topical overdose of PATADAY occurs, the eye(s) may be flushed with tap water.
Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see Dosage Forms, Composition and Packaging section of the Product Monograph.
Olopatadine, a structural analog of doxepin, is a non-steroidal, non-sedating, topically effective anti-allergic molecule that exerts its effects through multiple distinct mechanisms of action.
Olopatadine is a mast cell stabilizer and a potent, selective histamine H1 antagonist (10,12) that inhibits the in vivo type 1 immediate hypersensitivity reaction (13). Olopatadine inhibits the release of mast cell inflammatory mediators [i.e., histamine, tryptase, prostaglandin D2 and TNFα (4,10,12,13)] as demonstrated in in vitro studies and confirmed in patients (8). Olopatadine is also an inhibitor of pro-inflammatory cytokine secretion from human conjunctival epithelial cells (14).
In two placebo-controlled, two-way crossover cardiac repolarization studies, no signal of QT interval prolongation was observed relative to placebo following twice daily 5 mg oral doses for 2.5 days in 102 healthy volunteers, or following twice daily 20 mg oral doses for 13.5 days in 32 healthy volunteers. In addition, no evidence of QT interval prolongation was observed, relative to placebo, in 429 perennial allergic rhinitis patients given olopatadine hydrochloride nasal spray, 665 micrograms twice daily for up to 1 year.
Following topical ocular administration in man, olopatadine was shown to have low systemic exposure. Two studies in healthy volunteers (totalling 24 subjects) dosed bilaterally with Olopatadine 0.15% ophthalmic solution once every 12 hours for 2 weeks demonstrated plasma concentrations to be generally below the quantitation limit of the assay (<0.5 ng/mL).
In multiple oral dose studies, olopatadine plasma concentrations were shown to increase in proportion to the dose increment. The elimination half-life in plasma was 7-14 hours, and elimination was predominantly through renal excretion. Approximately 60-70% of the oral dose was recovered in the urine as parent drug. Peak plasma concentrations of the active metabolite, N-desmethyl olopatadine and inactive N-oxide metabolite were low, less than 1% and 3% of parent, respectively.
Effectiveness in paediatric patients has not been established. No overall difference in safety has been observed between paediatric and adult patients.
No overall differences in safety and effectiveness have been observed between elderly and other adult patients.
In multiple oral dose studies, plasma concentrations of olopatadine are higher in female subjects, however, the differences are small and not clinically meaningful.
No specific pharmacokinetic study examining the effect of race has been conducted.
No specific pharmacokinetic study examining the effect of hepatic impairment was conducted. Since metabolism of olopatadine is a minor route of elimination, no adjustment of the dosing regimen of PATADAY is warranted in patients with hepatic impairment.
The mean plasma Cmax values for olopatadine following single intranasal doses of olopatadine hydrochloride nasal spray 0.6% (665 μg/spray) were not markedly different between healthy subjects (18.1 ng/mL) and patients with mild, moderate and severe renal impairment (range 15.5 to 21.6 ng/mL). Plasma AUC was 2.5-fold higher in patients with severe impairment (creatinine clearance <30 mL/min/1.73m2). Predicted peak steady-state plasma concentrations of olopatadine in patients with renal impairment following administration of olopatadine hydrochloride ophthalmic solution, 0.1% are at least 10-fold lower than those observed following administration of olopatadine nasal spray 0.6%, and approximately 300-fold lower than those observed following the safe and well-tolerated administration of 20 mg oral doses for 13.5 days. These findings indicate that no adjustment of the dosing regimen of PATADAY is warranted in patients with renal impairment.
A summary of the patient demographics for each of the 7 studies relevant to the evaluation of the efficacy of PATADAY is provided in Table 1. Overall, these demographics are representative of the population that would be expected to receive this medicinal product.
Table 1: Summary of trial design and patient demographics for clinical trials
| Study # | Trial design | Dosage, route of administration and duration | Study subjects (n=number) | Mean age (Range) | Gender |
| C-00-36 CAC | randomized, double-masked, placebo-controlled | PATADAY or placebo, 1 drop each eye at each visit, dosed contra-laterally; visits on 3 non-consecutive days | n = 45 | 42.3 yrs (19 – 70) | 18 M 27 F |
| C-01-18 CAC | randomized, double-masked, placebo-controlled | PATADAY, placebo, or PATADAY and placebo dosed contra-laterally, 1 drop each eye at each visit, visits on 2 non-consecutive days | n = 36 | 38.1 yrs (20-58) | 16 M 20 F |
| C-01-100 CAC | randomized, double-masked, placebo-controlled | PATADAY (OU), placebo (OU), PATADAY (OS) and placebo (OD), or PATADAY (OD) and placebo (OS), 1 drop each eye at each visit, visits on 2 non-consecutive days | n = 92 | 39.2 yrs (20-67) | 38 M 54 F |
| C-02-67 Environmental (grass) | randomized, double-masked, placebo-controlled parallel group | PATADAY or placebo, 1 drop each eye once daily, 10 weeks | n = 260 | 36.4 yrs (11-75) | 123 M 137 F |
| C-04-60 Environmental (grass) | randomized, double-masked, placebo-controlled parallel group | PATADAY or placebo, 1 drop each eye once daily, 6 weeks | n = 287 | 36.4 yrs (10-81) | 127 M 160 F |
| C-01-10 Environmental (ragweed) | randomized, double-masked, placebo-controlled, parallel group | PATADAY or placebo, 1 drop each eye once daily, 12 weeks | n = 240 | 37.3 (10-66) | 94 M 146 F |
| C-01-90 Environmental (grass) | randomized, double-masked, placebo-controlled, parallel group | PATADAY or placebo, 1 drop each eye once daily, 12 weeks | n = 239 | 37.4 (10-73) | 94 M 145 F |
| OU= both eyes, OD=right eye, OS=left eye | |||||
Conjunctival Allergen Challenge (CAC) Studies
Three studies were conducted to assess the safety and efficacy of PATADAY versus placebo in the treatment of allergen-mediated conjunctivitis using the CAC model at 27 minutes (onset-of-action), and either 16 hours or 24 hours or both (duration-of-action), after instillation. All three studies demonstrated that PATADAY dosed once daily was statistically superior to placebo in the treatment of ocular itching, has a rapid onset-of-action and a prolonged duration-of-action.
Table 2: CAC Itching Results from Contralateral Eye Analyses in Studies with PATADAY
| Onset-of-Action | 24Hr Duration-of-Action | 16Hr Duration-of-Action | ||||||||||||||
| time post-challenge | time post-challenge | time post-challenge | ||||||||||||||
| 3 min | 5 min | 7 min | 10 min | 20 min | 3 min | 5 min | 7 min | 10 min | 20 min | 3 min | 5 min | 7 min | 10 min | 20 min | ||
| C-00-36 PATADAY -Placebo | Mean Diff | -1.31 | -1.60 | -1.13 | -0.93 | -0.99 | -0.65 | -0.93 | -0.88 | -0.39 | ||||||
| pvalue | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.014 | |||||||
| C-01-18 PATADAY -Placebo | Mean Diff | -1.50 | -1.67 | -0.79 | -1.25 | -1.04 | -0.50 | |||||||||
| pvalue | 0.0002 | 0.0003 | 0.0180 | 0.0011 | 0.0044 | 0.0456 | ||||||||||
| C-01-100 PATADAY -Placebo | Mean Diff | -1.56 | -1.66 | -1.53 | -0.98 | -1.07 | -1.07 | |||||||||
| pvalue | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | ||||||||||
| Shaded areas indicate that ocular itching was not evaluated at these time-points; bold numbers indicate statistical significance. | ||||||||||||||||
Four environmental studies were designed to assess the safety and efficacy of PATADAY in comparison with placebo in the treatment of the signs and symptoms of seasonal allergic conjunctivitis. All studies were randomized, double-masked, placebo-controlled, multi-centre, parallel group studies. Three studies (C-02-67, C-04-60, and C-01-90) enrolled patients with a history of seasonal allergic conjunctivitis, a positive diagnostic skin prick test for grass antigen within the past 2 years, and a positive response to grass in the Conjunctival Allergen Challenge model of the required magnitude. One study (C-01-10) enrolled patients with a positive skin prick test for ragweed antigen. Daily pollen counts were recorded for each study site.
Clinical Study C-02-67
Two hundred and sixty (260) patients were enrolled in this 10-week environmental study. The primary efficacy analysis was based on the subject self-evaluation of the frequency of ocular itching during the three days prior to each weekly assessment visit. The results showed that PATADAY statistically significantly reduced the effects of pollen on ocular itching relative to vehicle when dosed once a day (Figure 1).
Figure 1: Mean Scores for Itching Frequency by Visit Day (Intent-to-Treat) (C-02-67)
 |
An analysis of the slopes of the lines measuring the effects of pollen on ocular itching also showed a statistically significant difference between PATADAY and placebo when pollen counts were taken into consideration.
The secondary analysis showed that PATADAY, dosed once a day, statistically significantly reduced the effects of pollen on daily itching severity when compared to vehicle (Table 3).
Table 3: Mean Itching Severity during 14 Consecutive Days of Peak Pollen (Intent-to-Treat) (C-02-67)
| ITCHING | ||
| PATADAY | Mean | 1.10 |
| Std | 0.92 | |
| N | 127 | |
| PLACEBO | Mean | 1.48 |
| Std | 1.04 | |
| N | 129 | |
| Difference from Vehicle | -0.38 | |
| p-value (t-test) | 0.0023 | |
Clinical Study C-04-60
Two hundred and eighty-seven (287) patients were enrolled in this 6-week environmental study. Severity scores for daily ocular itching, as recorded by patients three times per day in their diaries, were statistically significantly lower compared to placebo in the morning, mid-day, and evening when averaged over the 14 consecutive days of the peak pollen period. Additionally, the average diary itching scores are statistically significantly reduced in patients treated with PATADAY compared with placebo (Table 4).
Table 4: Average Diary Itching Over the Peak Pollen Period by Time (Intent-to-Treat) (C-04-60)
| Average Diary Itching | |||||
| Mean | Std | N | P-value | ||
| Morning | PATADAY | 0.55 | 0.60 | 144 | 0.0204 |
| Vehicle | 0.72 | 0.64 | 143 | ||
| Mid-Day | PATADAY | 0.50 | 0.61 | 144 | 0.0130 |
| Vehicle | 0.69 | 0.63 | 143 | ||
| Evening | PATADAY | 0.54 | 0.65 | 144 | 0.0084 |
| Vehicle | 0.74 | 0.67 | 143 | ||
Clinical Study C-01-10
A total of 240 patients were enrolled in this 12-week environmental study during ragweed season. The primary efficacy endpoint was subject self-evaluation of the frequency scores of ocular itching over a 12-week study period. The primary efficacy endpoint did not show any statistically significant difference between PATADAY and placebo in this study.
Clinical Study C-01-90
A total of 239 patients were enrolled in a 12-week environmental study during grass season. The primary efficacy endpoint was subject self-evaluation of the worst daily ocular itching averaged over a two-week, peak pollen period. The primary efficacy endpoint did not show any statistically significant difference between PATADAY and placebo in this study. The planned secondary efficacy analysis showed that PATADAY statistically significantly reduced the effects of pollen on ocular itching.
Olopatadine is an anti-allergic agent that exerts its effects through multiple distinct mechanisms of action. Olopatadine is a mast cell stabilizer and a potent, selective histamine H1 antagonist (11) that inhibits the in vivo type 1 immediate hypersensitivity reaction. In vitro studies have demonstrated the ability of olopatadine to stabilize rodent basophils and human conjunctival mast cells and inhibit immunologically-stimulated release of histamine. In addition, olopatadine inhibits the release of other mast cell inflammatory mediators [i.e., histamine, tryptase, prostaglandin D2 and TNFα (4,10,12,13)] as demonstrated in in vitro studies. Olopatadine is a selective histamine H1 receptor antagonist in vitro and in vivo as demonstrated by its ability to inhibit histamine binding and histamine-stimulated vascular permeability in the conjunctiva following topical ocular administration (12). Olopatadine is also an inhibitor of pro-inflammatory cytokine secretion from human conjunctival epithelial cells (14). Decreased chemotaxis and inhibition of eosinophil activation has also been reported (6,9). Olopatadine is devoid of effects on alpha-adrenergic, dopamine, muscarinic type 1 and 2, and serotonin receptors.
Olopatadine had no observed effect on heart rate, cardiac conduction (PR and QRS interval duration), cardiac repolarization (QT duration) or wave form morphology relative to placebo in 2 double-masked, placebo controlled, 2-way crossover studies of 102 subjects given 5-mg oral doses of olopatadine every 12 hours for 2.5 days and 32 subjects given 20-mg oral doses twice-daily for 13.5 days. No clinically relevant or statistically significant changes in mean QTcF (determined to be the most appropriate heart correction formula for both study populations) at steady-state from baseline were observed in either study. A categorical analysis of QTc (< 30 ms, 30 ms-60 ms, or > 60 ms) showed no statistically significant differences between olopatadine and placebo in both studies. An analysis of the maximal change from baseline in QTcF showed the difference was higher for placebo than for olopatadine.
Systemic bioavailability data upon topical ocular administration of PATADAY are not available. Following topical ocular administration in man, olopatadine was shown to have low systemic exposure. Two studies in normal volunteers (totalling 24 subjects) dosed bilaterally with Olopatadine 0.15% ophthalmic solution once every 12 hours for 2 weeks demonstrated plasma concentrations to be generally below the quantitation limit of the assay (< 0.5 ng/mL). Samples in which olopatadine was quantifiable were typically found within 2 hours of dosing and ranged from 0.5 to 1.3 ng/mL. These plasma concentrations were greater than 300 fold below those observed with a well-tolerated 20 mg oral multiple-dose regimen. In oral studies, olopatadine was found to be well absorbed. The half-life in plasma was 7-14 hours, and elimination was predominantly through renal excretion. Approximately 60-70% of the dose was recovered in the urine as parent drug. Two metabolites, the mono-desmethyl and the N-oxide, were detected at low concentrations in the urine.
REFERENCES
4. Cook EB, Stahl JL, Barney NP, Graziano FM. Olopatadine inhibits TNFα release from human conjunctival mast cells. Ann Allergy Asthma Immumol 84:504-508, 2000.
6. Ikemura T, Manabe H, Sasaki Y, Ishu H, Onuma K, Miki I, Kase H, Sato S, Kitamura S, Ohmori K. KW-4679, an antiallergic drug, inhibits the production of inflammatory lipids in human polymorphonuclear leukocytes and guinea pig eosinophils. Int Arch Allergy Immunol 110:57-63, 1996.
8. Leonardi A, Abelson MB. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans. Clin Ther 25:2539–52, 2003.
9. Ohmori K, Ishii H, Sasaki Y, Ikemura T, Manabe H, Kitamura S. Effects of KW-4679, a new orally active antiallergic drug, on antigen induced bronchial hyperresponsiveness, airway inflammation and immediate and late asthmatic responses in guinea pigs. Int Arch Allergy Immunol 110:64-72, 1996.
10. Sharif NA, Xu SX, Miller ST, Gamache DA, Yanni JM. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. JPET 278:1252-1261, 1996.
11. Sharif NA, Xu SX, Yanni JM. Olopatadine (AL-4943A): Ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and antiallergic agent for use in allergic conjunctivitis. J Ocular Pharmacol 12:401-407, 1996.
12. Weimer LK, Gamache DA, Yanni JM. Histamine-stimulated cytokine secretion from human conjunctival epithelial cells: Inhibition by histamine H1 antagonists. Int Arch Allergy Immunol 115:288-293, 1998.
13. Yanni JM, Stephens DJ, Miller ST, Weimer LK, Graff G, Parnell D, Lang LS, Spellman JM, Brady MT, Gamache DA. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/ antihistaminic agent. J Ocular Pharmacol Ther 12:389-400, 1996.
14. Yanni JM, Miller ST, Gamache DA, Spellman JM, Xu SX, Sharif NA. Comparative effects of topical anti-allergy drugs on human conjunctival mast cells. Ann Allergy Asthma Immumol 79:541-545, 1997.
PATADAY®
(olopatadine hydrochloride) ophthalmic solution
This leaflet is part III of a three-part "Product Monograph" published when PATADAY® was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about PATADAY. Contact your doctor or pharmacist if you have any questions about the drug.
ABOUT THIS MEDICATION
What the medication is used for:
PATADAY is used for the treatment of itchy eyes associated with seasonal allergic conjunctivitis.
Allergic conjunctivitis: Some materials (allergens) like pollens, house dust or animal fur may cause allergic reactions resulting in itching, redness as well as swelling of the surface of your eye.
What it does:
PATADAY is a medicine for treatment and control of allergic conditions of the eye. It works in two different ways by reducing and controlling the intensity of the allergic reaction.
When it should not be used:
PATADAY should not be used if you are allergic (hypersensitive) to olopatadine hydrochloride or any of the other ingredients (see What the non-medicinal ingredients are).
Tell your doctor if you have allergies.
Do not use PATADAY in children under the age of 16 years.
What the medicinal ingredient is:
olopatadine hydrochloride
What the nonmedicinal ingredients are:
Preservative: benzalkonium chloride
Other ingredients include: dibasic sodium phosphate, edetate disodium, povidone, purified water and sodium chloride. Tiny amounts of hydrochloric acid or sodium hydroxide are sometimes added to maintain proper pH balance.
What dosage forms it comes in:
Ophthalmic solution (eye drops). Each mL contains 2 mg olopatadine.
WARNINGS AND PRECAUTIONS
BEFORE you use PATADAY talk to your doctor or pharmacist.
Pregnancy or breast-feeding
If you are pregnant, or planning to become pregnant, talk to your doctor before you use PATADAY. If you are breast-feeding, do not use PATADAY; it may get into your milk.
Use of PATADAY and use of contact lenses
Use of PATADAY with other eye drops or ointments
Driving and using machines: You may find that your vision is blurred for a time just after you use PATADAY. Do not drive or use machines until your vision is clear.
INTERACTIONS WITH THIS MEDICATION
Please tell your doctor if you are taking or have recently taken any other medicines, even products you have bought yourself without prescription or natural health products.
There are no known drugs that interact with PATADAY.
PROPER USE OF THIS MEDICATION
PATADAY is an eye drop. Only use it in your eye(s).
If you are using other eye drops, wait at least 5 minutes before putting in PATADAY and the other eye drops. If you are using an eye ointment, you should apply it last.
Usual dose:
Adults: 1 drop in each affected eye once daily.
 |
1
 |
2
Instructions for use:
Overdose:
If you think you have used too much PATADAY, contact a healthcare professional, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.
If you get too much in your eyes, rinse it all out with warm water. Don’t put in any more drops until it’s time for your next regular dose.
Missed Dose:
If you forget to use PATADAY, use a single drop as soon as you remember, and then go back to your regular routine. Do not use a double dose to make up for the one missed.
SIDE EFFECTS AND WHAT TO DO ABOUT THEM
A small number of people who use PATADAY may get side effects. They can be unpleasant, but most of them disappear rapidly.
You can usually continue using the drops, unless the effects are serious. If you're worried, talk to a doctor or pharmacist.
Side effects may include:
In the eye:
Other areas of your body:
If you notice any side effects, other than discomfort, please inform your doctor or pharmacist.
| SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM | ||||
| Symptom / effect | Talk with your doctor or pharmacist | Stop taking drug and call your doctor or pharmacist | ||
| Only if severe | In all cases | |||
| Rare | Allergic reactions: swelling of the mouth and throat, shortness of breath, hives, severe itching and rash | √ | ||
This is not a complete list of side effects. For any unexpected effects while taking PATADAY, contact your doctor or pharmacist.
HOW TO STORE IT
Store at room temperature or between 4-25°C.
Throw away the bottle at the end of your treatment.
Keep out of the reach and sight of children.
REPORTING SIDE EFFECTS
You can report any suspected side effects associated with the use of health products to Health Canada by:
NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.
MORE INFORMATION
This document plus the full Product Monograph, prepared for health professionals can be found on the Health Canada website or by contacting the sponsor, Novartis Pharmaceuticals Canada Inc. at: 1-800-363-8883.
